Germany’s CureVac has said it has started a mid-stage study testing its experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter.
CureVac has dosed the first patient with its experimental Covid-19 vaccine in the trial taking place in Peru and Panama and expects data on older adults in the fourth quarter.
The vaccine developer plans to start the global trial after data from the ongoing studies.
